3rd Drug Discovery for Neurodegeneration Conference

Washington, DC - February 2-3, 2009

Park Hyatt Washington DC

Presented by the Alzheimer's Drug Discovery Foundation

General Information  Speakers  Program Accommodations  Registration  CME Scholarships  Sponsorship  Supporters

PROGRAM

Click here to access the webcast of the 2008 edition of this conference.

February 1, 2009

5:00–7:00 pm

On-Site Registration

February 2, 2009

7:45 – 8:30 am

Registration & Continental Breakfast

8:30 – 8:35

Welcome & Opening Remarks - Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation

8:35 – 9:00

Plenary Talk: Overview of Drug Discovery for Neurodegenerative Disease - Howard Fillit, MD, Alzheimer's Drug Discovery Foundation - Click here to read session synopsis

I. Basics of Medicinal Chemistry - Click here to read session synopsis

Chair: D. Martin Watterson, PhD, Northwestern University

9:00 – 9:10

Session Overview – D. Martin Watterson, PhD 

9:10 – 9:30

Fundamentals of Medicinal Chemistry Refinement for CNS Compounds - Alan P. Kozikowski, PhD, University of Illinois at Chicago

9:30 – 9:40

Q&A

9:40 – 10:00

Rational Design and Medicinal Chemistry Refinement for Biosynthetic Enzymes - Richard B. Silverman, PhD, Northwestern University

10:00 – 10:10

Q&A

10:1010:25

BREAK

10:25 – 10:45

Ligand Development for Growth Factor Receptors - Frank M. Longo, MD, PhD, Stanford University

10:45 – 10:55

Q&A

10:55 – 11:15

Secretase Inhibitors: From Inhibitors towards CNS Drugs - Jordan Tang, PhD, Oklahoma Medical Research Foundation

11:15 – 11:25

Q&A

11:25 am – 11:45 pm

Hits to Leads to Drugs: What Makes a Chemical a Drug - Christopher Lipinski, PhD, Melior Discovery, Inc.  

11:45 – 11:55

Q&A

11:55 am – 1:00 pm

LUNCH

II. Hits & Leads: Early Phases of Drug Discovery - Click here to read session synopsis

Chair: Marcie Glicksman, PhD, Harvard NeuroDiscovery Center

1:00 – 1:10

Session Overview – Marcie Glicksman, PhD

1:10 – 1:30

Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates - Marcie Glicksman, PhD, Harvard NeuroDiscovery Center

1:30 – 1:40

Q&A

1:40 – 2:00

Role of In Vitro Models in Drug Discovery for Neurodegenerative Disease - Linda Jo Van Eldik, PhD, Northwestern University

2:00 – 2:10

Q&A

2:10 – 2:30

In Vitro Toxicity Testing: What, Why & How - Karen L. Steinmetz, PhD, DABT, SRI International

2:30 – 2:40

Q&A

2:40 – 2:55

BREAK

III. Pre-Clinical Proof-of-Concept & Development - Click here to read session synopsis

Chair: Edward G. Spack, PhD, SRI International

2:55 – 3:05

Session Overview – Edward Spack, PhD

3:05 – 3:25

Characteristics of Compounds that Cross the Blood Brain Barrier - William A. Banks, MD, Saint Louis University School of Medicine

3:25 – 3:35

Q&A

3:35 – 3:55

Requirements for a Lead Compound to Become a Clinical Candidate - Nancy G. Wehner, PhD, Elan Pharmaceuticals

3:55 – 4:05

Q&A

4:05 – 4:25

Behavioral Testing in Neurodegenerative Disease - Daniela Brunner, PhD, PsychoGenics, Inc.

4:25 – 4:35

Q&A

4:35 – 4:55

The Basics of Pre-Clinical Development - Edward G. Spack, PhD, SRI International

4:55 – 5:05

Q&A

5:05 – 5:25

What Companies Look for in a Partner - Thomas Argentieri, PhD, Wyeth Pharmaceuticals

5:25 – 5:35

Q&A

5:35 – 5:45

Closing Remarks - Howard Fillit, MD, Alzheimer's Drug Discovery Foundation

5:45 – 7:00

NETWORKING RECEPTION

February 3, 2009

8:00 – 8:30 am

Continental Breakfast

8:30 – 8:40

Welcome & Opening Remarks - Suzana Petanceska, PhD, National Institute on Aging

IV. Issues in Technology Transfer: Interactions and Intellectual Property - Click here to read session synopsis

Chair: Kathleen A. Denis, PhD, Rockefeller University

8:40  – 8:45

Session Overview – Kathleen A. Denis, PhD

8:45 – 9:15

Working Effectively with Your TTO: Roles and Responsibilities - Kathleen A. Denis, PhD, Rockefeller University

9:15 – 9:25

Q&A

9:25 – 9:55

Intellectual Property 101: A Primer For Investigators - Colin G. Sandercock, Proskauer Rose LLP

9:55 – 10:05

Q&A

10:05 – 10:35

Creating Relationships with Industry: Consulting, Research, MTA's and Patent Licensing - Louis P. Berneman, PhD, Texelerate

10:35 – 10:45

Q&A

10:55 – 11:15

Should You Start a Biotechnology Company? - John S. Swartley, PhD, University of Pennsylvania

11:15 – 11: 25

Q&A

11:25 – 11:35

BREAK

V.  Ask the Experts: Drug Discovery for Neurodegenerative Disease - Click here to read session synopsis

Chair: Todd Sherer, PhD, Michael J. Fox Foundation for Parkinson's Research

11:35  – 11:40

Breakout Session Overview – Todd Sherer, PhD

11:40 am – 12:50 pm

Alzheimer’s Disease - Frank M. Longo, MD, PhD, Stanford University

 

Parkinson’s Disease - P. Jeffrey Conn, PhD, Vanderbilt University

 

Huntington’s Disease - Leticia Toledo-Sherman, PhD, CHDI Foundation

  

Amyotrophic Lateral Sclerosis - Jeffrey Rothstein, MD, PhD, Johns Hopkins University

 

Progressive Multiple Sclerosis - Fred D. Lublin, MD, Mount Sinai School of Medicine

12:50  – 1:50

LUNCH

VI. Resources and Services For Advancing Drug Discovery - Click here to read session synopsis

Chair: Lorenzo Refolo, PhD, National Institute on Neurological Disorders and Stroke

1:50 – 2:00

Session Overview - Lorenzo Refolo, National Institute on Neurological Disorders and Stroke

2:00 – 2:20

ADDME - Avoiding Drug Development Mistakes Early - Katya Tsaioun, PhD, Apredica

2:20 – 2:30

Q&A

2:30 – 2:50

Resources at the National Institute of Health - Suzana Petanceka, PhD, National Institute on Aging, and Lorenzo Refolo, PhD, National Institute of Neurological Disorders and Stroke

2:50 – 3:00

Q&A

3:00 – 3:20

Academic Models of Drug Discovery Services - D. Martin Watterson, PhD, Northwestern University

3:20 – 3:30

Q&A

3:30 – 4:00

Foundation Resources Panel

Chair: Howard Fillit, MD, ADDF

Panelists: Antony Horton, PhD, International Rett Syndrome Foundation;  Todd Sherer, PhD, Michael J. Fox Foundation for Parkinson's Research; Lucie Bruijn, PhD, ALS Association; and Cynthia Joyce, SMA Foundation.

4:00 – 4:10

Q&A

4:10 – 4:20

Closing Remarks - Howard Fillit, MD, Executive Director, ADDF

top